ACADIA Pharmaceuticals
Committed to developing treatments for neurological disorders.
Launch date
Employees
Market cap
CAD3.7b
Enterprise valuation
CAD3.1b (Public information from Sep 2024)
Share price
$16.42 ACAD
San Diego California (HQ)
Financials
Estimates*
USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | 442m | 484m | 517m | 726m | 952m | 1.1b | 1.2b |
% growth | 30 % | 10 % | 7 % | 40 % | 31 % | 11 % | 11 % |
EBITDA | (287m) | (170m) | (224m) | (67.8m) | 72.2m | 154m | 313m |
% EBITDA margin | (65 %) | (35 %) | (43 %) | (9 %) | 8 % | 14 % | 27 % |
Profit | (282m) | (168m) | (216m) | (61.3m) | 88.2m | 156m | 277m |
% profit margin | (64 %) | (35 %) | (42 %) | (8 %) | 9 % | 15 % | 23 % |
EV / revenue | 17.8x | 6.7x | 4.2x | 6.5x | 2.3x | 1.9x | 1.5x |
EV / EBITDA | -27.4x | -19.0x | -9.7x | -69.3x | 30.5x | 13.1x | 5.5x |
R&D budget | 319m | 239m | 362m | 352m | - | - | - |
R&D % of revenue | 72 % | 49 % | 70 % | 48 % | - | - | - |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
$6.0m | Series A | ||
$3.0m | Series B | ||
$10.7m | Series D | ||
N/A | Grant | ||
$25.0m | Series F | ||
N/A | N/A | IPO | |
$10.0m | Post IPO Equity | ||
$20.0m | Post IPO Equity | ||
$15.0m | Post IPO Equity | ||
N/A | $86.4m | Post IPO Equity | |
* | N/A | $316m | Post IPO Equity |
* | N/A | $288m | Post IPO Equity |
Total Funding | CAD61.0m |
Recent News about ACADIA Pharmaceuticals
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by ACADIA Pharmaceuticals
EditACQUISITION by ACADIA Pharmaceuticals Aug 2020